Mar 16, 2017 by David LiangAre These 2 Biotechs Diamonds in the Rough?Do Adamas Pharmaceuticals and Amicus Therapeutics have the potential to power your portfolio higher?
Mar 13, 2017 by David LiangSynergy Pharmaceuticals: Approval, Now What?Is Synergy a buy on the post-approval dip?
Mar 10, 2017 by David LiangThe 3 Drugs Powering Celgene to the Top of Your PortfolioIs Celgene the best biotech to buy right now?
Mar 7, 2017 by David LiangThe Best Bet in the Growing Genetic Testing Market: Genetic Health vs. InvitaeWhich company is best situated to profit off this secular growth trend?
Mar 6, 2017 by David LiangHas Biodelivery Sciences Finally Turned the Corner?Will Biodelivery Sciences have any more success commercializing Belbuca?
Feb 28, 2017 by David LiangCan Shares of Aquinox Pharmaceuticals Continue to Rocket Higher?Will this past failure lead to a future success story?
Feb 23, 2017 by David LiangCan This Marijuana Stock Add Some Green to Your Portfolio? A Closer Look at Corbus Pharmaceuticals After a 600% rally, can shares continue to move higher?
Feb 17, 2017 by David LiangWhat This Legendary Value Investor Thinks About the Markets Right NowWhen Seth Klarman speaks, the market listens.
Feb 17, 2017 by David LiangRiding High? Or Just a Puff of Smoke? A Closer Look at Medical Marijuana Inc.How risky is this play on the growing cannabis industry?
Feb 14, 2017 by David LiangCaution: Acadia Pharmaceuticals Is OvervaluedDoes shaky phase 2 data justify a $5 billion valuation?
Feb 13, 2017 by David LiangWhy Shares of Cara Therapeutics Are Up Over 75% Since the Start of 2017After a meteoric rise since the start of the year, can these shares keep climbing?
Feb 11, 2017 by David LiangA Potential $20 Billion Indication? 2 Must-Have Biotechs Taking on Alzheimer's DiseaseIs biotech giant Biogen or scrappy startup Acadia the better buy in Alzheimer's?
Feb 1, 2017 by David LiangPacific Biosciences: A Small Cap Gem in the Genomics MarketDoes a better product mean Pacific Biosciences is finally ready to take on Illumina?
Jan 19, 2017 by David LiangDid Roche Just Hand Illumina Pacific Biosciences’ Head on a Platter?What does Roche’s partnership termination with Pacific Biosciences mean for Illumina shareholders?
Jan 5, 2017 by David LiangA David and Goliath Story: Can Small-Cap Synergy Pharmaceuticals Take on Ironwood Pharmaceuticals?Has the success of Synergy Pharmaceuticals' plecanatide put Ironwood on the warpath?
Jan 4, 2017 by David LiangDid Biogen Just Throw in the Towel to Celgene?Was the failure of MT-1303 the last stone in Biogen's crumbling autoimmune empire?
Nov 29, 2016 by David Liang2 Red-Hot Biotechs to Buy Ahead of FDA DecisionsIs it worth rolling the dice on Flexion and Synergy?
Nov 17, 2016 by David LiangCan Flexion Therapeutics Add Some Muscle to Your Portfolio?Shares of small-cap Flexion Therapeutics have rallied more than 100% in the past six months. Is there more upside to come?
Nov 10, 2016 by David Liang3 Reasons to Sell BiogenIncreasing competition within the multiple sclerosis market makes Biogen king of a crumbling empire. Is it time to ring the register?
